Cerubidine
Active substance: Daunorubicin
Manufacturer: Bedford Laboratories
Extract from the prescribing information:
"Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy."
"Special attention must be given to the potential cardiac toxicity of Cerubidine, particularly in infants and children."
The above has been extracted from the Cerubidine prescribing information on the Bedford Laboratories webpages.